3-Arylamino-2-(sulfonylbenzamide)cyclopentyl(hexyl)enecarboxylic acid derivatives and preparation methods and applications thereof

The binding of existing carbonic anhydrase II inhibitors has been solved by designing 3-substituted arylamine-2-(4-sulfonamidebenzamido)cyclopentene(hexane)-1-ene-1-carboxylic acid derivatives The problem of insufficient results has achieved efficient inhibition of carbonic anhydrase II and has significant anti-glaucoma drug potential.

CN114920671BActive Publication Date: 2024-11-01SHENYANG PHARMA UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210317949.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-29
Publication Date
2024-11-01
Estimated Expiration
2042-03-29

AI Technical Summary

Technical Problem

The existing carbonic anhydrase II inhibitors can only bind to one or two active sites of the enzyme, resulting in insufficient inhibitory activity and ineffective reduction of intraocular pressure, which in turn cannot effectively treat glaucoma.

Method used

Design and synthesize 3-substituted arylamine-2-(4-sulfonamidebenzamido)cyclopentene (hexane)-1-ene-1-carboxylic acid derivatives that simultaneously bind zinc in enzymes Ionic, hydrophobic and hydrophilic regions achieve more efficient enzyme inhibition through multiple forces such as coordination and hydrogen bonds.

Benefits of technology

This compound significantly improves the inhibitory effect of carbonic anhydrase II, has potential anti-glaucoma drug applications, and can more effectively reduce intraocular pressure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003569471250000021
    Figure BDA0003569471250000021
  • Figure BDA0003569471250000041
    Figure BDA0003569471250000041
  • Figure BDA0003569471250000051
    Figure BDA0003569471250000051
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and relates to 3-substituted aromatic amino-2-(4-sulfonamidobenzamide)cyclopentyl(hexyl)-1-ene-1-carboxylic acid derivatives and preparation methods and medical uses thereof. The compound is represented by the general formula (1), in which the substituents are as shown in the specification; the compound has three active fragments, sulfonamide, substituted aromatic amine and free carboxyl, and can react with Zn in carbonic anhydrase II. 2+ It forms multiple forces such as coordination bonds, van der Waals forces and hydrogen bonds with hydrophobic and hydrophilic regions, thereby inhibiting the catalytic activity of the enzyme and has potential application as an anti-glaucoma drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology and relates to 3-substituted aromatic amino-2-(4-sulfonamidobenzamido)cyclopentyl(hexyl)-1-ene-1-carboxylic acid derivatives and a preparation method and medical use thereof. Background Art

[0002] Carbonic anhydrases (CAs) are a class of zinc-containing metalloenzymes that are ubiquitous in organisms. They mainly catalyze the reversible hydration reaction of carbon dioxide, and this simple reaction is necessary for many physiological processes, such as gas exchange, ion exchange, and maintaining the balance of intracellular and extracellular pH. Among them, CAII catalyzes CO in ciliary epithelial cells. 2 and H 2 O eventually produces HCO 3 - , secreted into the aqueous humor through the luminal membrane, because the solution must maintain electrical neutrality, Na + Increase to the aqueous humor, while driving Cl - Migrate to the aqueous humor, thus forming a high osmotic pressure in the aqueous humor, which prompts water to flow into the aqueous humor, maintaining the ion balance and flow of the aqueous humor. However, the intraocular pressure of glaucoma patients increases due to poor aqueous humor reflux. CA II inhibitors can inhibit the activity of CA, causing HCO 3 - The generation of HCO is reduced 3 - 、Na + , Cl - It enters the aqueous humor and reduces the production of aqueous humor, thereby lowering intraocular pressure. It is clinically used to treat glaucoma.

[0003] The catalytic domain of CA II is the key area for inhibitor molecule binding. The catalytic center is located in a conical cavity that runs from the surface of the protein to the center and is divided into two parts: the hydrophobic region and the hydrophilic region. 2+ It is located at the bottom of this cavity. The direction of CA II inhibitor development will be to seal and occupy zinc ions, hydrophilic regions and hydrophobic regions. Most of the current CA II inhibitors can only bind to one or two active sites, resulting in low enzyme inhibition activity. Therefore, it is necessary to obtain a CA II inhibitor that can bind zinc ions, hydrophobic regions and hydrophilic regions at the same time. Summary of the invention

[0004] The invention aims to design and synthesize 3-substituted aromatic amino-2-(4-sulfonamidobenzamido)cyclopentyl(hexyl)-1-ene-1-carboxylic acid derivatives, and their preparation method and medical use.

[0005] To achieve the above purpose, the present invention adopts the following technical solution:

[0006] A 3-arylamino-2-(sulfonylbenzamide)cyclopentane(hexane)carboxylic acid derivative, the compound is shown in the general formula (1)

[0007]

[0008] In the general formula:

[0009] n = 1 or 2;

[0010] R 1 is selected from H, hydroxyl, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy which are unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino; amino which is unsubstituted or substituted by the following groups, such as the following groups are selected from C1-6 alkyl, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C2-6 alkenylcarbonyl or C2-6 alkynylcarbonyl; sulfamide or amide which are unsubstituted or substituted by the following groups, wherein the following groups replacing the amino group in the sulfamide or amide are selected from C1-6 alkyl, C1-6 aminoalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C2-6 alkenylcarbonyl or C2-6 alkynylcarbonyl; phenyl, naphthyl, benzyl, pyridine ring, pyrazole ring, pyrrole ring, pyrimidine ring, quinoline ring, imidazole ring, morpholine ring, piperazine ring, pyridazine ring, pyrazine ring, piperidine ring, thiophene ring, pyran ring, indole ring, furan ring, unsubstituted or substituted by at least one of the following groups, the following groups are selected from hydroxyl, hydroxymethyl, mercapto, amino, sulfamide, carboxyl, ester, cyano, nitro, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-7 cycloalkyl, benzyloxycarbonyl, C1-6 haloalkyl;

[0011] R 2 is selected from potassium ion, sodium ion, lithium ion, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy which are unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino;

[0012] Or, optical isomers and diastereomers of the compound represented by general formula (1).

[0013] Preferably, in the general formula:

[0014] n = 1 or 2;

[0015] R 1 is selected from H, hydroxy, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, amino, sulfamide, amide, phenyl which is unsubstituted or substituted by at least one of the following groups, naphthyl, benzyl, pyridine ring, pyrazole ring, pyrrole ring, pyrimidine ring, quinoline ring, imidazole ring, morpholine ring, piperazine ring, pyridazine ring, pyrazine ring, piperidine ring, thiophene ring, pyran ring, indole ring, furan ring, the following groups are selected from hydroxy, hydroxymethyl, thiol, amino, sulfamide, carboxyl, ester, cyano, nitro, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-7 cycloalkyl, benzyloxycarbonyl, C1-6 haloalkyl;

[0016] R 2 is selected from potassium ion, sodium ion, lithium ion, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy which are unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino;

[0017] Or, optical isomers and diastereomers of the compound represented by general formula (1).

[0018] Further preferably, in the general formula:

[0019] n = 1 or 2;

[0020] R 1 is selected from H, hydroxy, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, phenyl which is unsubstituted or substituted by at least one of the following groups, naphthyl, benzyl, pyridine ring, pyrazole ring, pyrrole ring, pyrimidine ring, quinoline ring, imidazole ring, morpholine ring, piperazine ring, pyridazine ring, pyrazine ring, piperidine ring, thiophene ring, pyran ring, indole ring, furan ring, the following groups are selected from hydroxy, hydroxymethyl, thiol, amino, sulfamide, carboxyl, ester, cyano, nitro, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-7 cycloalkyl, benzyloxycarbonyl, C1-6 haloalkyl;

[0021] R 2is selected from potassium ion, sodium ion, lithium ion, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy which are unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino;

[0022] Or, optical isomers or diastereomers of the compound represented by general formula (1).

[0023] In further preferred embodiment, in the general formula:

[0024] n = 1 or 2;

[0025] R 1 is selected from H, hydroxyl, phenyl, which is unsubstituted or substituted by at least one of the following groups, and naphthyl, wherein the following groups are selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-7 cycloalkyl, benzyloxycarbonyl, C1-6 haloalkyl;

[0026] R 2 is selected from potassium ion, sodium ion, lithium ion, ethyl which is unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino;

[0027] Or, optical isomers or diastereomers of the compound represented by general formula (1).

[0028] Still more preferably, in the general formula:

[0029] n = 1 or 2;

[0030] R 1 phenyl, naphthyl, which are unsubstituted or substituted by at least one of the following groups, and the following groups are selected from halogen, C1-6 alkyl, benzyloxycarbonyl, C1-6 haloalkyl;

[0031] R 2 is selected from potassium ion, sodium ion, ethyl which is unsubstituted or substituted by at least one of the following groups, wherein the following groups are selected from one or more of halogen, hydroxyl, cyano, nitro and amino;

[0032] Or, optical isomers or diastereomers of the compound represented by general formula (1).

[0033] More preferably, the compound represented by the general formula (1) is the following A1-A14, B1-B13, C1-C14, D1-D13 compounds and their optical isomers and diastereomers;

[0034]

[0035]

[0036]

[0037]

[0038] A method for preparing the compound, the reaction formula is as follows: first, cyclopentanone carboxylate (i.e., n=1) or cyclohexanone carboxylate (n=2) is treated with ammonium carbamate to obtain intermediate 1a or 1b, 1a or 1b is acylated with intermediate 2 to obtain intermediate 3a or 3b, intermediate 3a or 3b is brominated with copper bromide to obtain intermediate 4a or 4b, intermediate 4a or 4b undergoes a substitution reaction with a substituted aromatic amine to obtain a compound of general formula (1), or is hydrolyzed to obtain a compound of general formula (1);

[0039]

[0040] a. ammonium formate, methanol; b. thionyl chloride; c. pyridine, acetonitrile; d. copper bromide, acetonitrile; e. substituted aniline, potassium carbonate, sodium iodide, acetonitrile;

[0041]

[0042] f. Potassium hydroxide or lithium hydroxide or sodium hydroxide, tetrahydrofuran.

[0043] A pharmaceutical composition comprises the compound and its optically active form, diastereoisomer and a pharmaceutically acceptable carrier.

[0044] The invention discloses an application of a compound and a composition, and an application of the compound and its optically active form, diastereoisomer or the composition in preparing a drug for inhibiting carbonic anhydrase.

[0045] Application of the compound and its optically active form, diastereoisomer or the composition in preparing anti-glaucoma drugs.

[0046] The advantages of the present invention are:

[0047] The compounds of the present invention are obtained according to the three regions of the active center, hydrophilic region and hydrophobic region of the enzyme. The compounds have three active fragments of sulfonamide, substituted aromatic amine and free carboxyl in structure, which can react with Zn in carbonic anhydrase II. 2+ It forms multiple forces such as coordination bonds, van der Waals forces and hydrogen bonds with hydrophobic and hydrophilic regions, thereby inhibiting the catalytic activity of the enzyme and has potential application as an anti-glaucoma drug. DETAILED DESCRIPTION

[0048] The following examples will provide a better understanding of the compounds of the present invention and their preparation. These examples are intended to illustrate but not to limit the scope of the present invention.

[0049] Example 1: Ethyl 3-anilino-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A1)

[0050] Ethyl cyclopentanone carboxylate (3.53 g, 22.63 mmol), ammonium carbamate (4.41 g, 56.54 mmol), and 30 mL of methanol were added to a 100 mL eggplant-shaped bottle and stirred at room temperature for 1 h. The solvent was then evaporated under reduced pressure to obtain the crude product 1a as a colorless transparent solid without further purification.

[0051] Add p-sulfonamidobenzoic acid (10 g, 49.75 mmol), 125 mL of thionyl chloride, and 3 drops of N,N-dimethylformamide into a 250 mL eggplant-shaped bottle, stir, and reflux to react overnight. Then, evaporate the solvent under reduced pressure to obtain crude product 2 as a yellow solid, which does not require further purification.

[0052] Add intermediate 1a (3.50 g, 22.63 mmol), pyridine (2.68 g, 33.93 mmol), and acetonitrile 20 mL to a 100 mL eggplant-shaped bottle. Slowly drip the acetonitrile solution (20 mL) of intermediate 2 (5.42 g, 24.88 mmol) into the bottle under ice bath and stirring. Continue stirring for 30 min after the dropwise addition, then stir at room temperature overnight. Pour the reaction solution into 200 mL of water, and a yellow precipitate is generated. Filter, wash with water, and dry to obtain crude product 3a (4.42 g) with a yield of 57.78%. Mp 120.1–121.2℃; 1 H NMR (600 MHz, DMSO-d 6 )δ11.22(s,1H),8.03(s,4H),7.59(s,2H),4.22(q,J=7.1Hz,2H),3.22(t,J=7.7Hz,2H ),2.54–2.49(m,2H),1.95–1.87(m,2H),1.27(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 15 H 18 N 2 O 5 S[MH] - :337.0864,Found337.1225[MH] - .

[0053] Add intermediate 3a (2.03 g, 6.01 mmol) and 20 mL of acetonitrile to a 100 mL eggplant-shaped flask. Add copper bromide (2.77 g, 12.59 mmol) in batches under ice bath and stirring, and continue stirring for 40 min. Add 30 mL of saturated sodium bicarbonate solution to quench the reaction, filter with suction, filter with diatomaceous earth, take the filtrate, extract with ethyl acetate (3x15 mL), combine the organic phases, dry over anhydrous sodium sulfate, evaporate the solvent under reduced pressure, and wash with methanol to obtain 4a as a white solid, with a yield of 1.50 g and a yield of 60.00%. Mp 131.1–132.2℃; 1 H NMR (600 MHz, DMSO-d 6 )δ10.79(s,1H),8.07(d,J=8.4Hz,2H),8.02(d,J=8.4Hz,2H),7.58(s,2H),6.19(d,J=5.9Hz,1H),4.24(q,J=7. 1Hz,2H),2.66–2.58(m,1H),2.55–2.48(m,2H),2.32–2.23(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 15 H 17 N 2 O 5 SBr[MH] - :416.2665,Found 416.2655[MH] - .

[0054] In a 100 mL eggplant-shaped bottle, intermediate 4a (0.21 g, 0.50 mmol), aniline (0.093 g, 1 mmol), potassium carbonate (0.1 g, 0.72 mmol), sodium iodide (0.007 g, 0.05 mmol), and acetonitrile 20 mL were added. The mixture was stirred at room temperature for 24 h, filtered with suction, and filtered with diatomaceous earth. The filtrate was taken, the solvent was evaporated under reduced pressure, and then separated by rapid silica gel column chromatography (petroleum ether (PE): ethyl acetate (EA) = 3:1) to obtain A1 as a yellow oil, with a yield of 0.12 g and a yield of 55.94%. 1 H NMR (400 MHz, DMSO-d 6)δ10.82(s,1H),7.99(s,4H),7.56(s,2H),7.08–7.04(m,2H),6.63(d,J= 7.8Hz,2H),6.54(t,J=7.3Hz,1H),5.80–5.78(m,1H),5.55–5.45(m,1H), 4.24(q,J=7.0Hz,2H),2.66–2.62(m,1H),2.50–2.45(m,1H),2.18–2.14(m,1H),1.76–1.73(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.forC 21 H 23 N 3 O 5 S[M+Na] + :452.1251,Found 452.1270[M+Na] + .

[0055] Example 2: Ethyl 3-(1-naphthylamino)-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A2)

[0056] The preparation method of the compound of Example 2 is the same as that of Example 1, using 4a (0.21 g, 0.50 mmol) and 1-naphthylamine (0.143 g, 1 mmol) as raw materials, referring to the synthesis method of A1, to obtain A2 as a yellow oil, with an amount of 0.16 g and a yield of 66.81%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.90(s,1H),8.13(d,J=8.5Hz,1H),7.98(s,4H),7.74(d,J=7.6Hz,1H),7.53(s,2H),7 .41–7.37(m,1H),7.32–7.30(m,2H),7.15(d,J=8.1Hz,1H),6.67(d,J=7.6Hz,1H),6.15(d ,J=6.9Hz,1H),5.65–5.63(m,1H),4.28(q,J=7.1Hz,2H),2.74–2.69(m,1H),2.60–2.54(m ,1H),2.33–2.28(m,1H),1.91–1.85(m,1H),1.29(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 25 H 25 N 3 O 5 S[M+Na] +:502.1407,Found 502.1414[M+Na] + .

[0057] Example 3: Ethyl 3-[(4-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A3)

[0058] The preparation method of the compound of Example 3 is the same as that of Example 1, using 4a (0.21 g, 0.50 mmol) and 4-methoxyaniline (0.12 g, 1 mmol) as raw materials, referring to the synthesis method of A1, to obtain A3 as a yellow oil, with an amount of 0.13 g and a yield of 56.64%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.80(s,1H),7.99(s,4H),7.55(s,2H),6.71(d,J=9.0Hz,2H),6.61(d,J=8.9Hz,2H),5.37(s,1H),5.30(s,1H),4.24(q,J=7.0Hz,2H) ,3.63(s,3H),2.65–2.61(m,1H),2.45–2.43(m,1H),2.14–2.10(m,1H),1.78–1.72(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 25 N 3 O 6 S[M+H] + :460.1537,Found460.1546[M+H] + .

[0059] Example 4: Ethyl 3-[(3-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A4)

[0060] The preparation method of the compound of Example 4 is the same as that of Example 1, using 4a (0.21 g, 0.50 mmol) and 3-methoxyaniline (0.12 g, 1 mmol) as raw materials, referring to the synthesis method of A1, to obtain A4 as a yellow oil, with an amount of 0.18 g and a yield of 78.43%. 1 H NMR (400 MHz, DMSO-d 6)δ10.79(s,1H),7.99(s,4H),7.54(s,2H),6.97–6.93(m,1H),6.23(d,J=8.0Hz,1 H),6.21–6.19(m,1H),6.13(d,J=8.0Hz,1H),5.81(d,J=7.7Hz,1H),5.45–5.41(m, 1H),4.24(q,J=7.0Hz,2H),3.66(s,3H),2.66–2.63(m,1H),2.49–2.45(m,1H),2. 16–2.14(m,1H),1.76–1.73(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.forC 22 H 25 N 3 O 6 S[M+Na] + :482.1356,Found 482.1375[M+Na] + .

[0061] Example 5: Ethyl 3-[(4-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A5)

[0062] In a 100 mL eggplant-shaped bottle, intermediate 4a (0.21 g, 0.50 mmol), 4-fluoroaniline (0.11 g, 1 mmol), potassium carbonate (0.1 g, 0.72 mmol), sodium iodide (0.007 g, 0.05 mmol), and acetonitrile 20 mL were added. The mixture was stirred and refluxed for 2 h, filtered with suction, and filtered with diatomaceous earth. The filtrate was taken and the solvent was evaporated under reduced pressure. The mixture was separated by rapid silica gel column chromatography (petroleum ether (PE): ethyl acetate (EA) = 3:1) to obtain A5 as a yellow oil, with a yield of 0.15 g and a yield of 67.11%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.81(s,1H),7.99(s,4H),7.55(s,2H),6.94–6.88(m,2H),6.65–6.63(m,2H),5.71(d,J=7.8Hz,1H),5.50–5.40(m,1H),4.24(q,J= 6.8Hz,2H),2.65–2.63(m,1H),2.47–2.44(m,1H),2.15–2.13(m,1H),1.76–1.73(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O5 SF[M+Na] + :470.1156,Found470.1178[M+Na] + .

[0063] Example 6: Ethyl 3-[(3-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A6)

[0064] The preparation method of the compound of Example 6 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 3-fluoroaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A6 as a yellow oil, with an amount of 0.11 g and a yield of 49.22%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.82(s,1H),7.99(s,4H),7.55(s,2H),7.08–7.02(m,1H),6.44–6.3 8(m,2H),6.31–6.27(m,1H),6.20(d,J=7.7Hz,1H),5.46–5.44(m,1H),4 .25(q,J=7.0Hz,2H),2.68–2.64(m,1H),2.49–2.46(m,1H),2.21–2.17(m,1H),1.76–1.71(m,1H),1.25(t,J=7.0Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SF[M+Na] + :470.1156,Found470.1167[M+Na] + .

[0065] Example 7: Ethyl 3-[(4-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A7)

[0066] The preparation method of the compound of Example 7 is the same as that of Example 1, using 4a (0.21 g, 0.50 mmol) and 4-methylaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of A1, to obtain A7 as a yellow oil, with an amount of 0.12 g and a yield of 54.18%. 1 H NMR (400 MHz, DMSO-d 6)δ10.81(s,1H),7.99(s,4H),7.55(s,2H),6.88(d,J=8.2Hz,2H),6.55(d,J=8.1Hz,2H),5.53(d,J=7.4Hz,1H),5.43–5.39(m,1H),4.24(q ,J=7.0Hz,2H),2.67–2.63(m,1H),2.45–2.44(m,1H),2.14–2.11(m,4H),1.77–1.74(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 25 N 3 O 5 S[M+H] + :444.1588,Found 444.1605[M+H] + .

[0067] Example 8: Ethyl 3-[(3-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A8)

[0068] The preparation method of the compound of Example 8 is the same as that of Example 1, using 4a (0.21 g, 0.50 mmol) and 3-methylaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of A1, to obtain A8 as a yellow oil, with an amount of 0.12 g and a yield of 54.18%. 1 H NMR (400 MHz, DMSO-d 6 )δ11.16(s,1H),8.33(s,4H),7.89(s,2H),7.29–7.25(m,1H),6.77–6.75(m ,2H),6.70(d,J=7.4Hz,1H),6.02(d,J=7.6Hz,1H),5.79–5.75(m,1H),4.57( q,J=7.0Hz,2H),3.70(s,3H),2.98–2.94(m,1H),2.82–2.80(m,1H),2.49–2 .45(m,1H),2.10–2.05(m,1H),1.59(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 25 N 3 O 5 S[M+H] + :444.1588,Found 444.1606[M+H] + .

[0069] Example 9: Ethyl 3-[(4-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A9)

[0070] The preparation method of the compound of Example 9 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 4-bromoaniline (0.17 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A9 as a yellow oil, with an amount of 0.16 g and a yield of 63.12%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.81(s,1H),7.99(s,4H),7.54(s,2H),7.19(d,J=8.8Hz,2H),6.59(d,J=8.9Hz,2H),6.07(d,J=7.7Hz,1H),5.44–5.40(m,1H),4.24(q ,J=7.1Hz,2H),2.67–2.63(m,1H),2.49–2.45(m,1H),2.18–2.15(m,1H),1.77–1.74(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SBr[M+H] + :508.0536,Found 510.0541[M+H] + .

[0071] Example 10: Ethyl 3-[(3-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A10)

[0072] The preparation method of the compound of Example 10 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 3-bromoaniline (0.17 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A10 as a yellow oil, with an amount of 0.12 g and a yield of 47.34%. 1 HNMR (400 MHz, DMSO-d 6)δ10.82(s,1H),7.99(s,4H),7.55(s,2H),7.02–6.98(m,1H),6.79(s,1H ),6.67(d,J=8.9Hz,1H),6.61(d,J=8.9Hz,1H),6.20(s,1H),5.43(s,1H) ,4.25(q,J=7.1Hz,2H),2.66–2.64(m,1H),2.49–2.46(m,1H),2.23–2.19(m,1H),1.75–1.69(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SBr[M+H] + :508.0536,Found510.0538[M+H] + .

[0073] Example 11: Ethyl 3-[(4-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A11)

[0074] The preparation method of the compound of Example 11 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 4-chloroaniline (0.13 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A11 as a yellow oil, with an amount of 0.14 g and a yield of 60.48%. 1 HNMR (400 MHz, DMSO-d 6 )δ10.82(s,1H),7.99(s,4H),7.55(s,2H),7.08(d,J=8.9Hz,2H),6.63(d,J=8.9Hz,2H),6.04(s,1H),5.44(s,1H),4.24(t,J=7.1 Hz,2H),2.63–2.60(m,1H),2.49–2.45(m,1H),2.17–2.14(m,1H),1.75–1.67(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SCl[M+H] + :464.1041,Found 464.1064[M+H] + .

[0075] Example 12: Ethyl 3-[(3-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A12)

[0076] The preparation method of the compound of Example 12 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 3-chloroaniline (0.13 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A12 as a yellow oil, with an amount of 0.13 g and a yield of 56.16%. 1 HNMR (400 MHz, DMSO-d 6 )δ10.82(s,1H),7.99(s,4H),7.55(s,2H),7.06(t,J=8.0Hz,1H),6.64 (s,1H),6.58–6.53(m,2H),6.21(d,J=7.7Hz,1H),5.50–5.45(m,1H),4. 25(q,J=7.1Hz,2H),2.65–2.62(m,1H),2.49–2.46(m,1H),2.21–2.18(m,1H),1.73–1.70(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SCl[M+H] + :464.1041,Found464.1054[M+H] + .

[0077] Example 13: Ethyl 3-[(4-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A13)

[0078] The preparation method of the compound of Example 13 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 4-trifluoromethylaniline (0.16 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A13 as a yellow oil, with an amount of 0.12 g and a yield of 48.29%. 1 H NMR (400 MHz, DMSO-d 6)δ10.85(s,1H),7.99(s,4H),7.55(s,2H),7.37(d,J=8.5Hz,2H),6.73(d,J=8.5Hz,2H),6.65(s,1H),5.53(s,1H),4.26(q,J=7.1 Hz,2H),2.69–2.63(m,1H),2.54–2.50(m,1H),2.27–2.23(m,1H),1.77–1.72(m,1H),1.27(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 22 N 3 O 5 SF 3 [M+Na] + :520.1124,Found 520.1148[M+Na] + .

[0079] Example 14: Ethyl 3-[(3-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (A14)

[0080] The preparation method of the compound of Example 14 is the same as that of Example 5, using 4a (0.21 g, 0.50 mmol) and 3-trifluoromethylaniline (0.16 g, 1 mmol) as raw materials, referring to the synthesis method of A5, to obtain A14 as a yellow oil, with an amount of 0.15 g and a yield of 60.36%. 1 H NMR (400 MHz, DMSO-d 6 )δ10.81(s,1H),7.99(s,4H),7.55(s,2H),7.02–6.80(m,2H),6.72–6.50(m,2H),5.71(d,J=7.8Hz,1H),5.40(t,J=7.5Hz,1H),4.24(q, J=7.1Hz,2H),2.74–2.58(m,1H),2.49–2.43(m,1H),2.24–2.09(m,1H),1.81–1.67(m,1H),1.26(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 22 N 3 O 5 SF 3 [M+Na] + :520.1124,Found 520.1148[M+Na] + .

[0081] Example 15: Ethyl 3-(anilino)-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B1)

[0082] The preparation method of the compound of Example 15 is the same as that of Example 1, with ethyl cyclohexanonecarboxylate (3.85 g, 22.63 mmol) and ammonium carbamate (4.41 g, 56.54 mmol) as raw materials, referring to the synthesis method of 1a, 1b is obtained as a colorless transparent solid, and no further purification is required. 1b (3.82 g, 22.63 mmol) is used as raw material, referring to the synthesis method of 3a, 3b is obtained as a yellow solid, the amount is 4.51 g, and the yield is 56.66%. Mp119.2–120.3℃; 1 H NMR (600 MHz, DMSO-d 6 )δ12.17(s,1H),7.99(q,J=8.5Hz,4H),7.54(s,2H),4.17(q,J=7.1Hz,2H),3.04–2.90(m,2H),2.37 –2.27(m,2H),1.68–1.61(m,2H),1.61–1.54(m,2H),1.22(t,J=7.1Hz,3H).HRMS(ESI):Calcd.forC 16 H 20 N 2 O 5 S[MH] - :351.1020,Found 351.1038[MH] - .Using 3b (2.12 g, 6.01 mmol) as the raw material and referring to the synthesis method of 4a, 4b was obtained as a white solid with an amount of 1.60 g and a yield of 61.54%. Mp 127.2–128.4℃; 1 H NMR (600 MHz, DMSO-d 6 )δ10.75(s,1H),8.02(d,J=7.6Hz,2H),7.97(d,J=7.6Hz,2H),7.54(s,2H),5.97(s,1H),4.09(q,J=7.1Hz,2H),2.72–2.62(m, 1H),2.44–2.34(m,1H),2.25–2.17(m,1H),2.16–2.09(m,1H),1.88–1.77(m,2H),1.11(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 16 H 19 N 2 O 5 SBr[MH] -:429.0125,Found 431.0119[MH] - .Using 4b (0.22 g, 0.50 mmol) and aniline (0.093 g, 1 mmol) as raw materials and referring to the synthesis method of A1, B1 was obtained as a yellow oil with an amount of 0.13 g and a yield of 58.69%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.82(s,1H),7.99–7.86(m,4H),7.48(s,2H),6.74–6.55(m,5H),5.41(d,J=9.3Hz,1H),5.13(s,1H),4.15–4.10(m,2H),2.50–2. 45(m,1H),2.29–2.18(m,1H),1.85–1.79(m,1H),1.77–1.68(m,1H),1.64–1.51(m,1H),1.14(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 25 N 3 O 5 S[M+Na] + :466.1407,Found 466.1424[M+Na] + .

[0083] Example 16: Ethyl 3-(1-naphthylamino)-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B2)

[0084] The preparation method of the compound of Example 16 is the same as that of Example 15, using 4b (0.22 g, 0.50 mmol) and 1-naphthylamine (0.14 g, 1 mmol) as raw materials, referring to the synthesis method of B1, to obtain B2 as a yellow oil, with an amount of 0.17 g and a yield of 68.97%. 1 H NMR (600 MHz, DMSO-d 6)δ10.87(s,1H),8.00–7.85(m,4H),7.51(s,2H),7.13–6.98(m,2H),6.67(d, J=7.9Hz,2H),6.52–6.49(m,1H),5.89–5.71(m,1H),5.25–5.07(m,1H),4.23– 4.03(m,2H),2.61–2.51(m,1H),2.33–2.15(m,1H),1.91–1.82(m,1H),1.78– 1.67(m,1H),1.67–1.52(m,2H),1.16(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 26 H 27 N 3 O 5 S[M+Na] + :516.1564,Found 516.1539[M+Na] + .

[0085] Example 17: Ethyl 3-[(4-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B3)

[0086] The preparation method of the compound of Example 17 is the same as that of Example 15, using 4b (0.22 g, 0.50 mmol) and 4-methoxyaniline (0.12 g, 1 mmol) as raw materials, referring to the synthesis method of B1, to obtain B3 as a yellow oil, with an amount of 0.22 g and a yield of 93.02%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.82(s,1H),7.93–7.89(m,4H),7.50(s,2H),6.68(d,J=9.1Hz,2H),6.64( d,J=9.1Hz,2H),5.31(d,J=9.3Hz,1H),5.03(s,1H),4.13–4.10(m,2H),3.61( s,3H),2.50–2.45(m,1H),2.29–2.18(m,1H),1.85–1.79(m,1H),1.77–1.68(m ,1H),1.64–1.51(m,1H),1.14(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for[M+Na] + C 23 H 27 N 3 O 6 S:496.1513,Found 496.1544[M+Na]+ .

[0087] Example 18: Ethyl 3-[(3-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B4)

[0088] The preparation method of the compound of Example 18 is the same as that of Example 15, using 4b (0.22 g, 0.50 mmol) and 3-methoxyaniline (0.12 g, 1 mmol) as raw materials, referring to the synthesis method of B1, to obtain B4 as a yellow oil, with an amount of 0.18 g and a yield of 76.11%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.80(s,1H),7.93–7.89(m,4H),7.50(s,2H),6.93–6.91(m,1H),6.27(dd,J=8.0,2.1Hz, 1H),6.25–6.22(t,J=2.1Hz,1H),6.10(dd,J=8.0,2.1Hz,1H),5.82(d,J=9.0Hz,1H),5.10–5 .05(m,1H),4.16–4.08(m,2H),3.64(s,3H),2.57–2.51(m,1H),2.29–2.15(m,1H),1.88–1.8 0(m,1H),1.77–1.67(m,1H),1.66–1.55(m,2H),1.14(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 23 H 27 N 3 O 6 S[M+Na] + :496.1513,Found 496.1524[M+Na] + .

[0089] Example 19: Ethyl 3-[(4-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B5)

[0090] In a 100 mL eggplant-shaped bottle, intermediate 4b (0.22 g, 0.50 mmol), 4-fluoroaniline (0.11 g, 1 mmol), potassium carbonate (0.1 g, 0.72 mmol), sodium iodide (0.007 g, 0.05 mmol), and acetonitrile 20 mL were added. The mixture was stirred and refluxed for 2 h, filtered with suction, and filtered with diatomaceous earth. The filtrate was taken and the solvent was evaporated under reduced pressure. The mixture was separated by rapid silica gel column chromatography (petroleum ether (PE): ethyl acetate (EA) = 3:1) to obtain B5 as a yellow oil with a yield of 0.1 g and a yield of 43.38%. 1H NMR (600 MHz, DMSO-d 6 )δ10.88(s,1H),8.01–7.86(m,4H),7.51(s,2H),6.97–6.81(m,2H),6. 71–6.58(m,2H),5.73(d,J=8.8Hz,1H),5.08(s,1H),4.21–4.07(m,2H), 2.31–2.15(m,1H),1.87–1.76(m,1H),1.74–1.67(m,1H),1.65–1.53(m,2H),1.27–1.21(m,1H),1.15(t,J=7.0Hz,3H).HRMS(ESI):Calcd.forC 22 H 24 N 3 O 5 SF[M+Na] + :484.1313,Found 484.1315[M+Na] + .

[0091] Example 20: Ethyl 3-[(3-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B6)

[0092] The preparation method of the compound of Example 20 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 3-fluoroaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B6 as a yellow oil, with an amount of 0.13 g and a yield of 56.40%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.88(s,1H),7.93–7.89(m,4H),7.51(s,2H),7.02(q,J=8.0Hz,1H),6.48(dd,J=8.2,1. 7Hz,1H),6.43(dt,J=12.5,2.2Hz,1H),6.26(td,J=8.5,2.2Hz,1H),6.22(d,J=8.9Hz,1H), 5.12–5.08(m,1H),4.13(q,J=7.1Hz,2H),2.57–2.52(m,1H),2.31–2.19(m,1H),1.86–1.79 (m,1H),1.75–1.66(m,1H),1.67–1.56(m,2H),1.15(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 24 N 3 O 5SF[M+Na] + :484.1313,Found 484.1331[M+Na] + .

[0093] Example 21: Ethyl 3-[(4-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B7)

[0094] The preparation method of the compound of Example 21 is the same as that of Example 15, using 4b (0.22 g, 0.50 mmol) and 4-methylaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of B1, to obtain B7 as a yellow oil, with an amount of 0.2 g and a yield of 87.53%. 1 HNMR (600 MHz, DMSO-d 6 )δ10.82(s,1H),7.93–7.89(m,4H),7.50(s,2H),6.85(d,J=8.2Hz,2H),6.58( d,J=8.2Hz,2H),5.53(d,J=9.1Hz,1H),5.09(s,1H),4.18–4.08(m,2H),2.50– 2.46(m,1H),2.26–2.19(m,1H),2.12(s,3H),1.87–1.78(m,1H),1.77–1.67(m ,1H),1.64–1.53(m,2H),1.14(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for[M+Na] + C 23 H 27 N 3 O 5 S:480.1564,Found 480.1567[M+Na] + .

[0095] Example 22: Ethyl 3-[(3-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B8)

[0096] The preparation method of the compound of Example 22 is the same as that of Example 15, using 4b (0.22 g, 0.50 mmol) and 3-methylaniline (0.11 g, 1 mmol) as raw materials, referring to the synthesis method of B1, to obtain B8 as a yellow oil, with an amount of 0.18 g and a yield of 78.77%. 1 H NMR (600 MHz, DMSO-d 6)δ10.83(s,1H),7.93–7.89(m,4H),7.50(s,2H),6.92–6.90(m,1H),6.48–6.45(m, 2H),6.33(d,J=7.4Hz,1H),5.69(d,J=9.0Hz,1H),5.12–5.08(m,1H),4.12(q,J=7. 1Hz,2H),2.56–2.50(m,1H),2.30–2.18(m,1H),2.15(s,3H),1.88–1.80(m,1H),1. 77–1.67(m,1H),1.64–1.52(m,2H),1.15(t,J=7.1Hz,3H).HRMS(ESI):Calcd.forC 23 H 27 N 3 O 5 S[M+Na] + :480.1564,Found 480.1587[M+Na] + .

[0097] Example 23: Ethyl 3-[(4-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B9)

[0098] The preparation method of the compound of Example 23 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 4-bromoaniline (0.17 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B9 as a yellow oil, with an amount of 0.12 g and a yield of 46.07%. 1 H NMR (600 MHz, DMSO-d 6 )δ10.94(s,1H),7.93–7.89(m,4H),7.50(s,2H),7.16(d,J=8.8Hz,2H),6 .62(d,J=8.9Hz,2H),6.10(d,J=8.8Hz,1H),5.11(s,1H),4.13(q,J=7.1Hz ,2H),2.56–2.51(m,1H),2.28–2.18(m,1H),1.84–1.76(m,1H),1.74–1.65(m,2H),1.64–1.55(m,1H),1.17(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 24 N 3 O 5 SBr[M+Na] + :544.0507,Found546.0505[M+Na]+ .

[0099] Example 24: Ethyl 3-[(3-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B10)

[0100] The preparation method of the compound of Example 24 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 3-bromoaniline (0.17 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B10 as a yellow oil, with an amount of 0.13 g and a yield of 49.90%. 1 HNMR (600 MHz, DMSO-d 6 )δ10.90(s,1H),7.93–7.89(m,4H),7.51(s,2H),6.99–6.94(m,1H),6.83 –6.80(m,1H),6.65–6.62(m,2H),6.22(d,J=8.9Hz,1H),5.12–5.08(m,1H ),4.13(q,J=7.1Hz,2H),2.57–2.52(m,1H),2.29–2.18(m,1H),1.85–1.77(m,1H),1.74–1.55(m,3H).1.15(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for C 22 H 24 N 3 O 5 SBr[M+Na] + :544.0507,Found546.0503[M+Na] + .

[0101] Example 25: Sodium 3-[(4-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B11)

[0102] The preparation method of the compound of Example 25 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 4-chloroaniline (0.13 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B11 as a yellow oil, with an amount of 0.1 g and a yield of 41.93%. 1 H NMR (600 MHz, DMSO-d 6)δ10.92(s,1H),7.93–7.89(m,4H),7.51(s,2H),7.05(d,J=8.7Hz,2H),6.6 6(d,J=8.8Hz,2H),6.07(d,J=8.9Hz,1H),5.12–5.08(m,1H),4.15–4.10(m,2 H),2.58–2.52(m,1H),2.30–2.18(m,1H),1.85–1.77(m,1H),1.75–1.65(m, 1H),1.66–1.54(m,2H),1.15(t,J=7.1Hz,3H).HRMS(ESI):Calcd.for[M+Na] + C 22 H 24 N 3 O 5 SCl:500.1017,Found500.1038[M+Na] + .

[0103] Example 26: Ethyl 3-[(3-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B12)

[0104] The preparation method of the compound of Example 26 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 3-chloroaniline (0.13 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B12 as a yellow oil, with an amount of 0.17 g and a yield of 71.28%. 1 HNMR (400 MHz, DMSO-d 6 )δ10.90(s,1H),7.93–7.89(m,4H),7.50(s,2H),7.06–7.00(m,1H),6.68–6.60(t ,J=2.0Hz,1H),6.59(dd,J=8.0,2.0Hz,1H),6.50(dd,J=8.0,2.0Hz,1H),6.23(d,J =8.8Hz,1H),5.12–5.08(m,1H),4.15–4.10(m,2H),2.53(s,1H),2.31–2.17(m,1H) ,1.85–1.75(m,1H),1.73–1.55(m,3H),1.16–1.12(m,3H).HRMS(ESI):Calcd.forC 22 H 24 N 3 O 5 SCl[M+Na] + :500.1017,Found 500.1012[M+Na]+ .

[0105] Example 27: Ethyl 3-[(4-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (B13)

[0106] The preparation method of the compound of Example 27 is the same as that of Example 19, using 4b (0.22 g, 0.50 mmol) and 4-trifluoromethylaniline (0.16 g, 1 mmol) as raw materials, referring to the synthesis method of B5, to obtain B13 as a yellow oil, with an amount of 0.15 g and a yield of 58.71%. 1 H NMR (400 MHz, DMSO-d 6 )δ11.04(s,1H),7.93–7.89(m,4H),7.50(s,2H),7.34(d,J=8.5Hz,2H),6.76(d,J=8.5Hz,2H),6.68(d,J=8.6Hz,1H),5.23(s,1H),4.1 5–4.10(m,2H),2.59–2.52(m,1H),2.34–2.18(m,1H),1.87–1.77(m,1H),1.72–1.58(m,3H),1.18–1.15(m,3H).HRMS(ESI):Calcd.for C 23 H 24 N 3 O 5 SF 3 [M+Na] + :534.1281,Found 534.1275[M+Na] + .

[0107] Example 28: Sodium 3-anilino-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C1)

[0108] Add intermediate A1 (0.1 g, 0.23 mmol) and 10 mL of tetrahydrofuran to a 100 mL eggplant-shaped flask. Add 0.92 mL (4 eq) of 1 M sodium hydroxide solution under ice bath and stirring, then stir at room temperature for 4 h. Distill off part of the solvent under reduced pressure, introduce carbon dioxide until the pH of the reaction solution is 7, distill off the solvent under reduced pressure, add 5 mL of tetrahydrofuran / 5 mL of ethanol, stir for 1 h, filter with suction, filter with diatomaceous earth, take the filtrate, distill off the solvent under reduced pressure, and separate by reverse phase column chromatography (methanol: water = 1:4) to obtain C1 as a yellow solid, with a yield of 0.096 g and a yield of 97.36%. Mp 170.1–171.2℃; 1 H NMR (400 MHz, DMSO-d 6)δ13.81(s,1H),8.00–7.92(m,4H),7.56(s,2H),7.04(t,J=7.8Hz,2H),6.62(d,J=7.9Hz,2H),6.50(t,J=7.2Hz,1H),5.61–5 .59(m,1H),5.33(s,1H),2.46–2.44(m,1H),2.36–2.32(m,1H),2.06–1.97(m,1H),1.69–1.65(m,1H).HRMS(ESI):Calcd.for C 19 H 18 N 3 O 5 SNa[M-Na] - :400.0973,Found 400.1381[M-Na] - .

[0109] Example 29: Sodium 3-(1-naphthylamino)-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C2)

[0110] The preparation method of the compound of Example 29 is the same as that of Example 28, with A2 (0.1 g, 0.21 mmol) as the raw material, referring to the synthesis method of C1, C2 is obtained as a yellow solid, the amount is 0.039 g, and the yield is 39.49%. Mp 174.2–175.2℃; 1 H NMR (600 MHz, DMSO-d 6 )δ13.95(s,1H),8.14(d,J=8.5Hz,1H),7.97(d,J=8.3Hz,2H),7.90(d,J=8.3Hz,2 H),7.73(d,J=8.1Hz,1H),7.39–7.37(m,1H),7.32–7.27(m,2H),7.13(d,J=8.1Hz, 1H),6.64(d,J=7.6Hz,1H),6.01(d,J=5.3Hz,1H),5.45(s,1H),2.55–2.53(m,1H) ,2.44–2.40(m,1H),2.21–2.18(m,1H),1.80–1.76(m,1H).HRMS(ESI):Calcd.forC 23 H 20 N 3 O 5 SNa[M-Na] - :450.1129,Found 450.1112[M-Na] - .

[0111] Example 30: Sodium 3-[(4-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C3)

[0112] The preparation method of the compound of Example 30 is the same as that of Example 28, with A3 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C3 is obtained as a yellow solid, with an amount of 0.057 g and a yield of 57.75%. Mp 173.1–174.3℃; 1 H NMR (600 MHz, DMSO-d 6 )δ13.81(s,1H),8.00(d,J=8.4Hz,2H),7.94(d,J=8.4Hz,2H),7.50(s,2H),6.70(d,J=8.9Hz,2H),6.60(d,J=8.9Hz,2H),5.23(s,1H), 5.11(d,J=6.6Hz,1H),3.64(s,3H),2.49–2.46(m,1H),2.35–2.32(m,1H),2.00–1.97(m,1H),1.67–1.65(m,1H).HRMS(ESI):Calcd.for C 20 H 20 N 3 O 6 SNa[M-Na] - :430.1078,Found430.1072[M-Na] - .

[0113] Example 31: Sodium 3-[(3-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C4)

[0114] The preparation method of the compound of Example 31 is the same as that of Example 28, with A4 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C4 is obtained as a yellow solid, with an amount of 0.055 g and a yield of 55.73%. Mp 173.2–174.4℃; 1 H NMR (600 MHz, DMSO-d 6)δ13.84(s,1H),8.00(d,J=8.5Hz,2H),7.94(d,J=8.5Hz,2H),7.54(s,2H),6. 93(t,J=8.1Hz,1H),6.22(d,J=8.1Hz,1H),6.18(s,1H),6.09(d,J=8.1Hz,1H), 5.64(d,J=6.9Hz,1H),5.30(t,J=6.9Hz,1H),3.65(s,3H),2.45–2.43(m,1H),2 .37–2.32(m,1H),2.02–1.99(m,1H),1.66–1.63(m,1H).HRMS(ESI):Calcd.for C 20 H 20 N 3 O 6 SNa[M-Na] - :430.1078,Found 430.1055[M-Na] - .

[0115] Example 32: Sodium 3-[(4-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C5)

[0116] The preparation method of the compound of Example 32 is the same as that of Example 28, with A5 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C5 is obtained as a yellow solid, with an amount of 0.075 g and a yield of 76.02%. Mp 177.8–179.4℃; 1 H NMR (600 MHz, DMSO-d 6 )δ13.85(s,1H),8.00(d,J=8.2Hz,2H),7.94(d,J=8.2Hz,2H),7.52(s,2H),6.89(t,J=8.7Hz,2H),6.61(m,2H),5.54(d,J=6 .7Hz,1H),5.27(s,1H),2.47–2.45(m,1H),2.38–2.34(m,1H),2.03–2.01(m,1H),1.63–1.61(m,1H).HRMS(ESI):Calcd.forC 19 H 17 N 3 O 5 SNaF[M-Na] - :418.0878,Found 418.1339[M-Na] - .

[0117] Example 33: Sodium 3-[(3-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C6)

[0118] The preparation method of the compound of Example 33 is the same as that of Example 28, with A6 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C6 is obtained as a yellow solid, with an amount of 0.071 g and a yield of 71.97%. Mp 177.6–179.3°C; 1 H NMR (600 MHz, DMSO-d 6 )δ13.80(s,1H),7.99(d,J=8.4Hz,2H),7.93(d,J=8.4Hz,2H),7.41(s,2H),7 .03(q,J=7.9Hz,1H),6.43(d,J=8.3Hz,1H),6.37(d,J=12.6Hz,1H),6.25(t,J =9.4Hz,1H),6.08(d,J=7.0Hz,1H),5.33–5.31(m,1H),2.47–2.44(m,1H),2. 38–2.34(m,1H),2.07–2.02(m,1H),1.63–1.61(m,1H).HRMS(ESI):Calcd.for C 19 H 17 N 3 O 5 SNaF[M-Na] - :418.0878,Found 418.0871[M-Na] - .

[0119] Example 34: Sodium 3-[(4-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C7)

[0120] The preparation method of the compound of Example 34 is the same as that of Example 28, with A7 (0.1 g, 0.23 mmol) as the raw material, referring to the synthesis method of C1, C7 is obtained as a yellow solid, the yield is 0.095 g, and the yield is 96.30%. Mp 171.1–172.5℃; 1 H NMR (400 MHz, DMSO-d 6)δ13.86(s,1H),7.99(d,J=8.4Hz,2H),7.93(d,J=8.4Hz,2H),7.52(s,2H),6.86(d,J=8.2Hz,2H),6.54(d,J=8.2Hz,2H),5.30 –5.27(m,2H),2.46–2.42(m,1H),2.37–2.30(m,1H),2.14(s,3H),2.02–1.97(m,1H),1.66–1.64(m,1H).HRMS(ESI):Calcd.for C 20 H 20 N 3 O 5 SNa[M-Na] - :414.1129,Found 414.1468[M-Na] - .

[0121] Example 35: Sodium 3-[(3-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C8)

[0122] The preparation method of the compound of Example 35 is the same as that of Example 28, with A8 (0.1 g, 0.23 mmol) as the raw material, referring to the synthesis method of C1, C8 is obtained as a yellow solid, the yield is 0.087 g, and the yield is 88.19%. Mp 171.3–172.3℃; 1 H NMR (400 MHz, DMSO-d 6 )δ13.86(s,1H),8.00–7.92(m,4H),7.55(s,2H),6.94–6.90(m,1H),6.42–6.40(m,2H),6.33(d,J=7.2Hz,1H),5.50(d,J=6.3Hz,1 H),5.31(s,1H),2.49–2.44(m,1H),2.37–2.35(m,1H),2.17(s,3H),2.03–1.98(m,1H),1.65–1.63(m,1H).HRMS(ESI):Calcd.for C 20 H 20 N 3 O 5 SNa[M-Na] - :414.1129,Found 414.1400[M-Na] - .

[0123] Example 36: Sodium 3-[(4-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C9)

[0124] The preparation method of the compound of Example 36 is the same as that of Example 28, with A9 (0.1 g, 0.20 mmol) as the raw material, referring to the synthesis method of C1, C9 is obtained as a yellow solid, with an amount of 0.043 g and a yield of 43.51%. Mp 180.1–181.6°C; 1 H NMR (600 MHz, DMSO-d 6 )δ13.88(s,1H),7.99(d,J=8.4Hz,2H),7.93(d,J=8.4Hz,2H),7.54(s,2H),7.16(d,J=8.8Hz,2H),6.57(d,J=8.8Hz,2H),5.94(d,J=6.9H z,1H),5.29(t,J=6.8Hz,1H),2.46–2.44(m,1H),2.36–2.32(m,1H),2.03–2.00(m,1H),1.61–1.60(m,1H).HRMS(ESI):Calcd.for[M-Na] - C 19 H 17 N 3 O 5 SNaBr:478.0078,Found480.0038[M-Na] - .

[0125] Example 37: Sodium 3-[(3-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C10)

[0126] The preparation method of the compound of Example 37 is the same as that of Example 28, with A10 (0.1 g, 0.20 mmol) as the raw material, referring to the synthesis method of C1, C10 is obtained as a yellow solid, with an amount of 0.073 g and a yield of 73.87%. Mp 180.2–181.4°C; 1 H NMR (600 MHz, DMSO-d 6 )δ13.79(s,1H),7.96(d,J=8.4Hz,2H),7.90(d,J=8.3Hz,2H),6.99–6.96(m,1H),6.76(s,1H),6.63–6.59(m,2H),6.08(d,J=7.0H z,1H),5.31(t,J=6.8Hz,1H),2.48–2.45(m,1H),2.38–2.33(m,1H),2.06–2.02(m,1H),1.62–1.59(m,1H).HRMS(ESI):Calcd.for C 19 H 17 N3 O 5 SNaBr[M-Na] - :478.0078,Found 480.0059[M-Na] - .

[0127] Example 38: Sodium 3-[(4-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C11)

[0128] The preparation method of the compound of Example 38 is the same as that of Example 28, with A11 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C11 is obtained as a yellow solid, with an amount of 0.052 g and a yield of 52.68%. Mp 178.0–178.9°C; 1 H NMR (600 MHz, DMSO-d 6 )δ13.85(s,1H),7.98(d,J=8.2Hz,2H),7.92(d,J=8.2Hz,2H),7.36(s,2H),7.05(d,J=8.6Hz,2H),6.62(d,J=8.6Hz,2H),5.90(d,J=6.9H z,1H),5.30(t,J=6.9Hz,1H),2.46–2.44(m,1H),2.37–2.33(m,1H),2.03–2.00(m,1H),1.61–1.59(m,1H).HRMS(ESI):Calcd.for[M-Na] - C 19 H 17 N 3 O 5 SNaCl:434.0583,Found434.0584[M-Na] - .

[0129] Example 39: Sodium 3-[(3-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C12)

[0130] The preparation method of the compound of Example 39 is the same as that of Example 28, with A12 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, C12 is obtained as a yellow solid, the amount is 0.05 g, and the yield is 50.66%. Mp 178.5–179.6℃; 1 H NMR (600 MHz, DMSO-d 6)δ13.78(s,1H),7.96(d,J=8.3Hz,2H),7.91(d,J=8.3Hz,2H),7.04(t,J=8.0Hz,1H),6.62(s,1H),6.56(d,J=8.2Hz,1H),6.49(d,J=7.7Hz,1H), 6.09(d,J=6.8Hz,1H),5.32(t,J=6.8Hz,1H),2.48–2.44(m,1H),2.38–2.36(m,1H),2.06–2.02(m,1H),1.62–1.59(m,1H).HRMS(ESI):Calcd.for C 19 H 17 N 3 O 5 SNaCl[M-Na] - :434.0583,Found434.0586[M-Na] - .

[0131] Example 40: Sodium 3-[(4-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C13)

[0132] The preparation method of the compound of Example 40 is the same as that of Example 28, with A13 (0.1 g, 0.20 mmol) as the raw material, referring to the synthesis method of C1, C13 is obtained as a yellow solid, the amount is 0.067 g, and the yield is 67.82%. Mp 177.1–177.6℃; 1 H NMR (600 MHz, DMSO-d 6 )δ13.87(s,1H),7.98(d,J=8.5Hz,2H),7.92(d,J=8.4Hz,2H),7.34(d,J=8.7Hz,4H),6.71(d,J=8.6Hz,2H),6.56(d,J=7.1 Hz,1H),5.40(s,1H),2.48–2.45(m,1H),2.38–2.31(m,1H),2.10–2.05(m,1H),1.63–1.60(m,1H).HRMS(ESI):Calcd.forC 20 H 17 N 3 O 5 SNaF 3 [M-Na] - :468.0846,Found 468.0846[M-Na] - .

[0133] Example 41: Sodium 3-[(3-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclopent-1-ene-1-carboxylate (C14)

[0134] The preparation method of the compound of Example 41 is the same as that of Example 28, with A14 (0.1 g, 0.20 mmol) as the raw material, referring to the synthesis method of C1, C14 is obtained as a yellow solid, with an amount of 0.094 g and a yield of 95.15%. Mp 177.6–178.8°C; 1 H NMR (600 MHz, DMSO-d 6 )δ13.86(s,1H),7.98(d,J=8.3Hz,2H),7.93(d,J=8.4Hz,2H),7.40(s,2H ),7.28–7.22(m,1H),6.87(d,J=8.7Hz,2H),6.77(d,J=7.5Hz,1H),6.29( d,J=7.0Hz,1H),5.37(t,J=6.8Hz,1H),2.49–2.44(m,1H),2.41–2.34(m,1H),2.12–2.03(m,1H),1.67–1.58(m,1H).HRMS(ESI):Calcd.for[M-Na] - C 20 H 17 N 3 O 5 SNaF 3 :468.0846,Found 468.0867[M-Na] - .

[0135] Example 42: Sodium 3-(anilino)-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D1)

[0136] The preparation method of the compound of Example 42 is the same as that of Example 28, using B1 (0.1 g, 0.23 mmol) as the raw material and referring to the synthesis method of C1, D1 is obtained as a yellow solid, with an amount of 0.088 g and a yield of 89.21%. Mp 167.0–168.4°C; 1 H NMR (600 MHz, DMSO-d 6 )δ15.24(s,1H),8.01(s,2H),7.88(s,2H),7.51(s,2H),7.01(s,2H),6.66(s,2H),6.45(s,1H),5. 66(s,2H),2.40(s,1H),2.15(s,1H),1.82(s,1H),1.64(s,1H),1.48(s,2H).HRMS(ESI):Calcd.for C20 H 20 N 3 O 5 SNa[M-Na] - :414.1129,Found 414.1133[M-Na] - .

[0137] Example 43: Sodium 3-(1-naphthylamino)-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D2)

[0138] The preparation method of the compound of Example 43 is the same as that of Example 28, with B2 (0.1 g, 0.20 mmol) as the raw material, referring to the synthesis method of C1, D2 is obtained as a yellow solid, the yield is 0.045 g, and the yield is 45.55%. Mp 170.2–171.2℃; 1 H NMR (600 MHz, DMSO-d 6 )δ15.31(s,1H),8.24(d,J=8.5Hz,1H),7.99(d,J=8.1Hz,2H),7.85(d,J=8.2Hz,2H),7.70 (d,J=8.1Hz,1H),7.50(S,2H),7.38–7.34(m,1H),7.28(s,2H),7.07(d,J=8.0Hz,1H),6.7 4(d,J=7.7Hz,1H),5.93(d,J=7.2Hz,1H),5.84(s,1H),2.46(s,1H),2.25–2.20(m,1H),1. 97(d,J=13.8Hz,1H),1.75–1.70(m,1H),1.60–1.50(m,2H).HRMS(ESI):Calcd.for[M-Na] - C 24 H 22 N 3 O 5 SNa:464.1286,Found464.1286[M-Na] - .

[0139] Example 44: Sodium 3-[(4-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D3)

[0140] The preparation method of the compound of Example 44 is the same as that of Example 28, with B3 (0.1 g, 0.21 mmol) as the raw material, referring to the synthesis method of C1, D3 is obtained as a yellow solid, the yield is 0.055 g, and the yield is 55.71%. Mp 170.4–171.6℃; 1H NMR (600 MHz, DMSO-d 6 )δ15.28(s,1H),8.01(d,J=8.5Hz,2H),7.88(d,J=8.4Hz,2H),7.50(s,2H),6.66(q,J=9.2Hz,4H),5.57(s,1H),5.16–5.12(m,1H), 3.62(s,3H),2.45–2.35(m,1H),2.19–2.10(m,1H),1.85–1.76(m,1H),1.69–1.61(m,1H),1.52–1.40(m,2H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 6 SNa[M-Na] - :444.1235,Found 444.1247[M-Na] - .

[0141] Example 45: Sodium 3-[(3-methoxyphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D4)

[0142] The preparation method of the compound of Example 45 is the same as that of Example 28, using B4 (0.1 g, 0.21 mmol) as the raw material and referring to the synthesis method of C1, D4 is obtained as a yellow solid, with an amount of 0.053 g and a yield of 53.68%. Mp 170.7–172.5°C; 1 H NMR (400 MHz, DMSO-d 6 )δ15.35(s,1H),8.01(d,J=8.4Hz,2H),7.87(d,J=8.4Hz,2H),7.49(s,2H),7 .00–6.81(m,1H),6.37–6.19(m,2H),6.05(d,J=9.9Hz,1H),5.69(d,J=8.6Hz, 1H),5.66–5.57(m,1H),3.64(s,3H),2.45–2.34(m,1H),2.23–2.07(m,1H),1. 88–1.75(m,1H),1.64–1.55(m,1H),1.53–1.39(m,2H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 6 SNa[M-Na] - :444.1235,Found 444.1645[M-Na] - .

[0143] Example 46: Sodium 3-[(4-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D5)

[0144] The preparation method of the compound of Example 46 is the same as that of Example 28, using B5 (0.1 g, 0.22 mmol) as the raw material and referring to the synthesis method of C1, D5 is obtained as a yellow solid, with an amount of 0.078 g and a yield of 79.03%. Mp 174.7–176.7°C; 1 H NMR (600 MHz, DMSO-d 6 )δ15.21(s,1H),8.01(d,J=8.1Hz,2H),7.89(d,J=8.0Hz,2H),6.88–6.84(m,2H),7.55(s,1H),6.66(dd,J=8.7,4.6Hz,2H),5.60(s ,2H),2.47–2.37(m,1H),2.22–2.14(m,1H),1.85–1.75(m,1H),1.65–1.59(m,1H),1.54–1.41(m,2H).HRMS(ESI):Calcd.for[M-Na] - C 20 H 19 N 3 O 5 SNaF:432.1035,Found 432.1033[M-Na] - .

[0145] Example 47: Sodium 3-[(3-fluorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D6)

[0146] The preparation method of the compound of Example 47 is the same as that of Example 28, using B6 (0.1 g, 0.22 mmol) as the raw material and referring to the synthesis method of C1, D6 is obtained as a yellow solid, with an amount of 0.074 g and a yield of 74.98%. Mp 174.8–176.0℃; 1 H NMR (400 MHz, DMSO-d 6)δ15.43(s,1H),8.01(d,J=8.4Hz,2H),7.87(d,J=8.4Hz,2H),7.49(s,2H),6.99( q,J=7.9Hz,1H),6.46(d,J=8.2Hz,1H),6.39(d,J=12.7Hz,1H),6.24–6.16(m,1H), 6.13(d,J=8.3Hz,1H),5.61(d,J=7.8Hz,1H),2.47–2.36(m,1H),2.21–2.08(m,1H) ,1.85–1.74(m,1H),1.67–1.55(m,1H),1.55–1.41(m,2H).HRMS(ESI):Calcd.forC 20 H 19 N 3 O 5 SNaF[M-Na] - :432.1035,Found 432.1456[M-Na] - .

[0147] Example 48: Sodium 3-[(4-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D7)

[0148] The preparation method of the compound of Example 48 is the same as that of Example 28, using B7 (0.1 g, 0.22 mmol) as the raw material and referring to the synthesis method of C1, D7 is obtained as a yellow solid, with an amount of 0.088 g and a yield of 89.17%. Mp 168.1–169.4°C; 1 H NMR (600 MHz, DMSO-d 6 )δ15.27(s,1H),8.00(d,J=8.2Hz,2H),7.87(d,J=8.2Hz,2H),7.50(s,2H),6.83(d,J=8.0Hz,2H),6.58(d,J=8.0Hz,2H),5.61(s,1H),5. 38(d,J=8.6Hz,1H),2.40(d,J=15.1Hz,1H),2.12(s,4H),1.82–1.75(m,1H),1.65–1.60(m,1H),1.50–1.40(m,2H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SNa[M-Na] - :428.1286,Found428.1658[M-Na] - .

[0149] Example 49: Sodium 3-[(3-methylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D8)

[0150] The preparation method of the compound of Example 49 is the same as that of Example 28, with B8 (0.1 g, 0.22 mmol) as the raw material, referring to the synthesis method of C1, D8 is obtained as a yellow solid, the yield is 0.066 g, and the yield is 66.88%. Mp 168.3–169.6℃; 1 H NMR (600 MHz, DMSO-d 6 )δ15.33(s,1H),8.00(d,J=8.2Hz,2H),7.87(d,J=8.2Hz,2H),7.46(s,2H),6.91–6.86(m,1H),6.46(s,2H),6.28(d,J=7.2Hz,1H),5.63(s, 1H),5.55(d,J=8.5Hz,1H),2.47–2.35(m,1H),2.15(s,4H),1.87–1.78(m,1H),1.67–1.57(m,1H),1.54–1.38(m,2H).HRMS(ESI):Calcd.for C 21 H 22 N 3 O 5 SNa[M-Na] - :428.1286,Found428.1685[M-Na] - .

[0151] Example 50: Sodium 3-[(4-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D9)

[0152] The preparation method of the compound of Example 50 is the same as that of Example 28, using B9 (0.1 g, 0.19 mmol) as the raw material and referring to the synthesis method of C1, D9 is obtained as a yellow solid, with an amount of 0.056 g and a yield of 56.65%. Mp 177.3–178.4°C; 1 H NMR (600 MHz, DMSO-d 6)δ15.41(s,1H),8.00(d,J=8.1Hz,2H),7.87(d,J=8.2Hz,2H),7.50(s,2H),7.13(d,J=8.5Hz,2H),6.60(d,J=8.6Hz,2H),6.01(d,J=8.3Hz ,1H),5.59(s,1H),2.46–2.36(m,1H),2.20–2.08(m,1H),1.83–1.73(m,1H),1.63–1.56(m,1H),1.54–1.42(m,2H).HRMS(ESI):Calcd.for C 20 H 19 N 3 O 5 SNaBr[M-Na] - :492.0234,Found 494.0654[M-Na] - .

[0153] Example 51: Sodium 3-[(3-bromophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D10)

[0154] The preparation method of the compound of Example 51 is the same as that of Example 28, with B10 (0.1 g, 0.19 mmol) as the raw material, referring to the synthesis method of C1, D10 is obtained as a yellow solid, with an amount of 0.077 g and a yield of 77.90%. Mp 177.3–178.5°C; 1 H NMR (600 MHz, DMSO-d 6 )δ15.52(s,1H),8.01(d,J=8.3Hz,2H),7.87(d,J=8.3Hz,2H),7.48(s,2H),6.96 –6.93(m,1H),6.78(s,1H),6.63(d,J=7.9Hz,1H),6.57(d,J=7.6Hz,1H),6.15(d, J=8.3Hz,1H),5.59(d,J=7.5Hz,1H),2.45–2.37(m,1H),2.18–2.09(m,1H),1.81– 1.73(m,1H),1.64–1.56(m,1H),1.53–1.43(m,2H).HRMS(ESI):Calcd.for[M-Na] - C 20 H 19 N 3 O 5 SNaBr:492.0234,Found 494.0714[M-Na] - .

[0155] Example 52: Sodium 3-[(4-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D11)

[0156] The preparation method of the compound of Example 52 is the same as that of Example 28, using B11 (0.1 g, 0.21 mmol) as the raw material and referring to the synthesis method of C1, D11 is obtained as a yellow solid, with an amount of 0.056 g and a yield of 56.71%. Mp 175.0–176.3°C; 1 H NMR (400 MHz, DMSO-d 6 )δ15.43(s,1H),8.00(d,J=8.3Hz,2H),7.87(d,J=8.3Hz,2H),7.49(s,2H),7.02(d,J=8.6Hz,2H),6.65(d,J=8.7Hz,2H),5.97(d,J=8.3Hz,1H) ,5.59(d,J=6.9Hz,1H),2.47–2.35(m,1H),2.22–2.07(m,1H),1.85–1.72(m,1H),1.68–1.56(m,1H),1.55–1.41(m,2H).HRMS(ESI):Calcd.for C 20 H 19 N 3 O 5 SNaCl[M-Na] - :448.0739,Found448.1228[M-Na] - .

[0157] Example 53: Sodium 3-[(3-chlorophenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D12)

[0158] The preparation method of the compound of Example 53 is the same as that of Example 28, using B12 (0.1 g, 0.21 mmol) as the raw material and referring to the synthesis method of C1, D12 is obtained as a yellow solid, with an amount of 0.044 g and a yield of 44.56%. Mp 175.4–176.5℃; 1 H NMR (400 MHz, DMSO-d 6)δ15.39(s,1H),8.01(d,J=8.3Hz,2H),7.88(d,J=8.3Hz,2H),7.50(s,2H),7.02 –6.98(m,1H),6.64(s,1H),6.59(d,J=8.2Hz,1H),6.45(d,J=7.6Hz,1H),6.16(d ,J=8.3Hz,1H),5.68–5.56(m,1H),2.49–2.34(m,1H),2.26–2.09(m,1H),1.87–1 .72(m,1H),1.67–1.57(m,1H),1.55–1.45(m,2H).HRMS(ESI):Calcd.for[M-Na] - C 20 H 19 N 3 O 5 SNaCl:448.0739,Found 448.1101[M-Na] - .

[0159] Example 54: Sodium 3-[(4-trifluoromethylphenyl)amino]-2-(4-sulfonamidobenzamido)cyclohex-1-ene-1-carboxylate (D13)

[0160] The preparation method of the compound of Example 54 is the same as that of Example 28, using B13 (0.1 g, 0.20 mmol) as the raw material and referring to the synthesis method of C1, D13 is obtained as a yellow solid, with an amount of 0.075 g and a yield of 75.89%. Mp 174.2–175.1°C; 1 H NMR (400 MHz, DMSO-d 6 )δ15.55(s,1H),8.00(d,J=8.3Hz,2H),7.87(d,J=8.3Hz,2H),7.50(s,2H)7.31(d,J=8.5Hz,2H),6.73(d,J=8.5Hz,2H),6.64(d,J=8 .0Hz,1H),5.68(d,J=7.1Hz,1H),2.49–2.37(m,1H),2.24–2.05(m,1H),1.86–1.72(m,1H),1.68–1.45(m,3H).HRMS(ESI):Calcd.for C 21 H 19 N 3 O 5 SNaF 3 [M-Na] - :482.1003,Found482.1439[M-Na] - .

[0161] Pharmacological studies of the present invention

[0162] The inhibitory effects of compounds A1, B1, C1-C14, and D1-D13 on carbonic anhydrase II were determined by enzymatic hydrolysis.

[0163] Dilute the substrate (4-nitrophenyl acetate) to 2mM with Tris assay buffer, dilute the enzyme to 20ng / uL with assay buffer, add 50uL 20ng / uL enzyme to a 96-well plate, add compounds A1, B1, C1-C14, D1-D13 prepared in the above examples as inhibitors, incubate at room temperature for 15min, add 25uL 2mM substrate to initiate the reaction, and read the absorbance at 348nm with a microplate reader after 10min. Test the inhibition rate of 6 different concentrations (2.00μM, 400.00nM, 80.00nM, 16.00nM, 3.20nM, 0.64nM) to obtain IC 50 The inhibition rate is calculated as follows:

[0164] % inhibition rate = (1-enzyme activity of sample well / enzyme activity of blank well) * 100

[0165]

[0166] a Human recombinant enzyme, assayed by the esterase method (4-nitrophenylacetate as substrate).

[0167] p-Sulfamoylbenzoic acid, p-Sulfamoylbenzoic acid

[0168] From the above, it can be seen that the inhibitory activities of A1, B1, C1-C14, and D1-D13 of the present invention are better than those of the positive control drug p-sulfonylaminobenzoic acid. The 3-substituted aromatic amino-2-(4-sulfonylaminobenzamide)cyclopent(hex)-1-ene-1-carboxylic acid derivatives designed and synthesized by the present invention simultaneously combine with the zinc ion, hydrophobic region and hydrophilic region of the CA II inhibitor, thereby significantly improving its inhibitory effect, and the effect of C1-C14 is more prominent.

Claims

1. A 3-arylamino-2-(sulfonylbenzamide)cyclopentane / hexenecarboxylic acid derivative, Features: The compound is shown in the general formula (1): In the general formula: n = 1 or 2; R 1 phenyl, naphthyl, which are unsubstituted or substituted by at least one of the following groups, the following groups are selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl; R 2 is selected from potassium ion, sodium ion, lithium ion, C1-6 alkyl which is unsubstituted or substituted by at least one of the following groups, the following groups are selected from halogen; or, optical isomers or diastereomers of the compound represented by the general formula (1).

2. The compound according to claim 1, Features: In the general formula: n = 1 or 2; R 1 phenyl, naphthyl, which are unsubstituted or substituted by at least one of the following groups, the following groups are selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl; R 2 is selected from potassium ion, sodium ion, lithium ion, ethyl which is unsubstituted or substituted by at least one of the following groups, the following groups are selected from halogen; or, optical isomers or diastereomers of the compound represented by the general formula (1).

3. The compound according to claim 2, Features: The compound represented by the general formula (1) is the following A1-A14, B1-B13, C1-C14, D1-D13 compounds and their optical isomers and diastereomers; 4. A method for preparing the compound according to claim 1, Features: The reaction formula is as follows: First, cyclopentanone carboxylate (i.e., n=1) or cyclohexanone carboxylate (n=2) is treated with ammonium carbamate to obtain intermediate 1a or 1b, 1a or 1b is acylated with intermediate 2 to obtain intermediate 3a or 3b, intermediate 3a or 3b is brominated with copper bromide to obtain intermediate 4a or 4b, intermediate 4a or 4b is subjected to substitution reaction with substituted aromatic amine to obtain a compound of general formula (1), or is further hydrolyzed to obtain a compound of general formula (1); a. Ammonium carbamate, methanol; b. Sulfoxide chloride; c. Pyridine, acetonitrile; d. Copper bromide, acetonitrile; e. Substituted aromatic amine, potassium carbonate, sodium iodide, acetonitrile; f. Potassium hydroxide or lithium hydroxide or sodium hydroxide, tetrahydrofuran.

5. A pharmaceutical composition, Features: The composition comprises the compound according to any one of claims 1 to 3 and its optical isomers, diastereomers and a pharmaceutically acceptable carrier.

6. Use of the compound according to any one of claims 1 to 3 and its optical isomers, diastereomers or the composition according to claim 5 in the preparation of a drug for inhibiting carbonic anhydrase.

7. Use of the compound according to any one of claims 1 to 3 and its optical isomers, diastereomers or the composition according to claim 5 in the preparation of anti-glaucoma drugs.

Citation Information

Patent Citations

  • Preparation method and medical application of sulfonamide compounds with glucuronic acid structures

    CN108003201A

  • Quinoline compound containing sulfonamide structure as well as preparation method and medical application thereof

    CN113045613A